SMYLS: A Self-Management Program for Youth Living with Sickle Cell Disease Save

Date Added
March 17th, 2019
PRO Number
Pro00084400
Researcher
Shannon Hudson

List of Studies


Profiles_link
Keywords
Adolescents, Blood Disorders, Pain, Pediatrics
Summary

The purpose of this study is to find out whether a web-based intervention using a mobile device is helpful for teens learning to care for and manage symptoms of their sickle cell disease. The intervention lasts 12 weeks with a 3-month follow up period, and uses a smartphone or a tablet. For more information, please contact Shannon at 843-792-9379.

Institution
MUSC
Recruitment Contact
Shannon Phillips
843-792-9379
phillipss@musc.edu

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Apremilast (CC 10004) in Pediatric Subjects from 6 through 17 Years with Moderate to Severe Plaque Psoriasis Save

Date Added
January 22nd, 2019
PRO Number
Pro00084118
Researcher
Lara Wine lee

List of Studies

Silhouette
Keywords
Drug Studies, Pediatrics, Skin
Summary

The purpose of this study is to test and compare the effects of an investigational (being tested) drug called apremilast to placebo in pediatric plaque psoriasis.
Participants who are determined to be eligible to participate will be assigned by chance (or randomized) to treatment with apermilast or placebo. At Week 16, participants will receive apremilast regardless of treatment group. Study and safety assessments, including questionnaires and blood draws, will be completed at study visits. The maximum amount of time participants will be in the study is 71 weeks (at least 19 visits).

Institution
MUSC
Recruitment Contact
Abby Powell
843-792-6690
powab@musc.edu

A PROSPECTIVE, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE THYROID FUNCTION OF PEDIATRIC SUBJECTS FROM BIRTH TO 3 YEARS EXPOSED TO ISOVUE® (IOPAMIDOL INJECTION) Save

Date Added
January 18th, 2019
PRO Number
Pro00084894
Researcher
Uwe o.p. Schoepf

List of Studies


Profiles_link
Keywords
Pediatrics
Summary

This study aims to collect data to determine if pediatric subjects up to 3 years of age develop abnormal thyroid function after exposure to iodinated contrast agents. This study will investigate subject thyroid function before and after administration of ISOVUE through pre-dose, 1 and 2 month post-dose follow-ups including TSH, T3, and T4 lab-work, and 6 and 12 month follow ups of a questionnaire.

Institution
MUSC
Recruitment Contact
Kalyan Chundru
8437921213
choudhar@musc.edu

Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy Save

Date Added
January 9th, 2019
PRO Number
Pro00084750
Researcher
Jacqueline Kraveka

List of Studies


Profiles_link
Keywords
Cancer/Leukemia, Cancer/Lymphoma, Pediatrics
Summary

This study is for patients that have been diagnosed with Leukemia or Lymphoma. and have been treated on one of the following studies: Pediatric Oncology Group (POG) 9404, 9425, 9426, or Dana Farber Cancer Institute (DFCI) ALL Consortium 95-01. The purpose of this study is to look at the heart function of patients selected by change to get DRZ compared to the heart function of patients selected by chance not to get DRZ. In this study, they will also look at gender, age at cancer diagnosis, current age, dose of chemotherapy, and if chest radiation influences the risk of early heard damage. Participants in this clinical trial are expected to come to one clinic visit.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients Save

Date Added
January 7th, 2019
PRO Number
Pro00083234
Researcher
Jacqueline Kraveka

List of Studies


Profiles_link
Keywords
Adolescents, Cancer, Pediatrics
Summary

This study is for patients that have been diagnosed with a pediatric brain tumor called medulloblastoma. The purpose of this study is to find out if a reduced dose of radiation to the whole brain and spine and less chemotherapy can be given to children and young adults with WNT subtype medulloblastoma without increasing the risk of the tumor coming back. Participants can expect to be in this study for about one year, and then followed for up to 10 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Prospective, observational, longitudinal study in pediatric patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not medically advisable Save

Date Added
December 20th, 2018
PRO Number
Pro00084090
Researcher
Lara Wine lee

List of Studies

Silhouette
Keywords
Pediatrics, Skin
Summary

This study will assess the features of children, younger than 12 years old, with moderate to severe eczema, also known as atopic dermatitis, when their condition is not adequately controlled with topical therapies (creams or lotions) or when those therapies are not medically advisable.

This is not a treatment study. You and your child will complete questionnaires describing how their condition effects them. Information related to your child's illness will be collected by reviewing their medical chart and by assessments performed by the study team. Participation in this study will involve at least 12 visits that will take place over a period of 5 years.

The information collected in this study may lead to an improved understanding of your child's illness and may provide healthcare providers with important information for treating atopic dermatitis in the future.

Institution
MUSC
Recruitment Contact
Susannah Wakefield
843-792-5935
dermresearch@musc.edu

Molecular pathogenesis of congenital vascular malformations Save

Date Added
December 13th, 2018
PRO Number
Pro00081757
Researcher
Wenbin Tan

List of Studies

Keywords
Pediatrics, Skin, Vascular
Summary

In this study, we will collect congenital vascular malformation (CVM) tissue samples to examine the vascular and neurological phenotypes in the lesions. We will develop a repository of the remaining CVM samples for our future research which will substantially decrease the need for specimen collections from future CVM subjects. We will also collect blood samples and characterize proteins and RNAs profiles from serum exosomes and metabolites from CVM patients, which will help us to understand the progressive mechanism of CVM.

Institution
Palmetto
Recruitment Contact
Wenbin Tan
803-2163816
wenbin.tan@uscmed.sc.edu

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Save

Date Added
November 21st, 2018
PRO Number
Pro00083280
Researcher
Jacqueline Kraveka

List of Studies


Profiles_link
Keywords
Cancer, Pediatrics
Summary

This study is for patients that have been diagnosed with a germ cell tumor. The purpose of this study is to compare the overall survival in patients treated with conventional-dose chemotherapy using the TIP regimen with high-dose chemotherapy (HDCT) plus ASCT using the TI-CE regimen as initial salvage treatment of patients with relapsed or refractory GCT. Participants can expect to be in this study for 12 to 16 weeks, depending on what group they are randomized to. Participants will continue to be followed for up to 5 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study Save

Date Added
November 19th, 2018
PRO Number
Pro00083220
Researcher
Jacqueline Kraveka

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Brain, Pediatrics
Summary

This study is for pediatric patients who have been diagnosed with Brain Tumors. The purpose of this study is to assess the feasibility of a home-based, computerized cognitive training program for patients with pediatric brain tumors who are undergoing cranial radiation therapy (CRT). Participants can expect to receive treatment on this study for about 5 to 9 weeks. Participants will complete additional testing sessions about 6 months after completing the cognitive training program.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Phase 2 Trial of XL184 (Cabozantinib), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Save

Date Added
November 19th, 2018
PRO Number
Pro00083227
Researcher
Jacqueline Kraveka

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Sarcoma, Pediatrics
Summary

This study is for patients that have been diagnosed with one of the following types of cancer: Ewing sarcoma, rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcomas, osteosarcoma, Wilms tumor or another rare tumor. The investigational drug used in this study is called cabozantinib, also known as XL184. The purpose of this study is to determine the response rate of XL184 in children and young adults. Participants in this clinical trial are expected to receive treatment for up to 5 years or until they develop side effects or the tumor worsens. Follow-up exams will be given at 30 days, 6 months and possibly yearly after study treatment completion.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login